Compare Novartis AG (NVS) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tyson Foods, Inc. — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Tyson Foods, Inc. trades at $52.31 (market cap $18.19B). The key difference: Novartis AG is far larger — about 15.1× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Tyson Foods, Inc. for 76 Days on average.
| NVS | TSN | |
|---|---|---|
Market Cap | $274.00B | $18.19B |
Volume | 1,852,137 | 3,320,883 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $68.75 |
52-Week Low | $121.80 | $50.47 |
Typical Hold Time | 82 Days | 76 Days |
Enterprise Value | $315.32B | $25.45B |
Dividend Yield | 3.31% | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Tyson Foods (TSN) trades at $52.34, up 0.71% with mixed technical signals showing neutral momentum. The company reported Q2 2026 EPS of $0.99 beating expectations, but faces margin pressure with net income margin at 1.03%. Recent news highlights dividend stability despite beef segment losses and ongoing securities investigations. Cash flow trends show operational strength with $2.16B from operations in 2025, though net cash flow remains negative.
The stock presents a value opportunity with P/S of 0.33 below industry averages, supported by 53% analyst buy ratings and $65.40 consensus target. However, margin compression, beef segment challenges, and legal investigations create near-term headwinds. Long-term prospects depend on operational improvements and successful navigation of current business challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
